Richard Parker1, Guruprasad P Aithal2, Ulrik Becker3, Dermot Gleeson4, Steven Masson5, Judith I Wyatt6, Ian A Rowe7. 1. Leeds Liver Unit, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK. Electronic address: richardparker@nhs.net. 2. NIHR Nottingham BRC, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham UK; Nottingham Digestive Diseases Centre, The School of Medicine, University of Nottingham, Nottingham, UK. 3. National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark; Gastrounit, Medical Division, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark. 4. Liver Unit, Sheffield Teaching Hospitals, Sheffield, UK. 5. Liver Transplant Unit, Freeman Hospital, Newcastle, UK. 6. Histopathology, Leeds Teaching Hospitals NHS Trust, Leeds, UK. 7. Leeds Liver Unit, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK; Leeds Institute for Data Analysis, University of Leeds, Leeds, UK.
Abstract
BACKGROUND & AIMS: To date, studies into the natural history of alcohol-related liver disease (ALD) have lacked long-term follow-up, large numbers of participants, or both. We performed a systematic review to summarise studies that describe the natural history of histologically proven ALD. METHODS: PubMed and Medline were searched for relevant studies according to pre-specified criteria. Data were extracted to describe the prevalence of ALD, histological progression of disease and mortality. Single-proportion meta-analysis was used to combine data from studies regarding rates of progression or mortality. RESULTS: Thirty-seven studies were included, reporting data from 7,528 participants. Amongst cohorts of hazardous drinkers, on average 15% had normal histological appearance, 27% had hepatic steatosis, 24% had steatohepatitis and 26% had cirrhosis. The annualised rates of progression of pre-cirrhotic disease to cirrhosis were 1% (0-8%) for patients with normal histology, 3% (2-4%) for hepatic steatosis, 10% (6-17%) for steatohepatitis and 8% (3-19%) for fibrosis. Annualised mortality was 6% (4-7%) in patients with steatosis and 8% (5-13%) in cirrhosis. In patients with steatohepatitis on biopsy a marked difference was seen between inpatient cohorts (annual mortality 15%, 8-26%) and mixed cohorts of inpatients and outpatients (annual mortality 5%, 2-10%). Only in steatosis did non-liver-related mortality exceed liver-specific causes of mortality (5% per year vs. 1% per year). CONCLUSIONS: These data confirm the observation that alcohol-related hepatic steatohepatitis requiring admission to hospital is the most dangerous subtype of ALD. Alcohol-related steatosis is not a benign condition as it is associated with significant risk of mortality. LAY SUMMARY: Knowledge of the natural history of a disease allows clinicians and patients to understand the risks that are associated with a medical condition. In this study we systematically gathered all the published data regarding the natural history of alcohol-related liver disease in people who had a liver biopsy. We used this data to define the prevalence of the disease, the annual risk of progression to cirrhosis and the annual risk of death at each stage of the disease.
BACKGROUND & AIMS: To date, studies into the natural history of alcohol-related liver disease (ALD) have lacked long-term follow-up, large numbers of participants, or both. We performed a systematic review to summarise studies that describe the natural history of histologically proven ALD. METHODS: PubMed and Medline were searched for relevant studies according to pre-specified criteria. Data were extracted to describe the prevalence of ALD, histological progression of disease and mortality. Single-proportion meta-analysis was used to combine data from studies regarding rates of progression or mortality. RESULTS: Thirty-seven studies were included, reporting data from 7,528 participants. Amongst cohorts of hazardous drinkers, on average 15% had normal histological appearance, 27% had hepatic steatosis, 24% had steatohepatitis and 26% had cirrhosis. The annualised rates of progression of pre-cirrhotic disease to cirrhosis were 1% (0-8%) for patients with normal histology, 3% (2-4%) for hepatic steatosis, 10% (6-17%) for steatohepatitis and 8% (3-19%) for fibrosis. Annualised mortality was 6% (4-7%) in patients with steatosis and 8% (5-13%) in cirrhosis. In patients with steatohepatitis on biopsy a marked difference was seen between inpatient cohorts (annual mortality 15%, 8-26%) and mixed cohorts of inpatients and outpatients (annual mortality 5%, 2-10%). Only in steatosis did non-liver-related mortality exceed liver-specific causes of mortality (5% per year vs. 1% per year). CONCLUSIONS: These data confirm the observation that alcohol-related hepatic steatohepatitis requiring admission to hospital is the most dangerous subtype of ALD. Alcohol-related steatosis is not a benign condition as it is associated with significant risk of mortality. LAY SUMMARY: Knowledge of the natural history of a disease allows clinicians and patients to understand the risks that are associated with a medical condition. In this study we systematically gathered all the published data regarding the natural history of alcohol-related liver disease in people who had a liver biopsy. We used this data to define the prevalence of the disease, the annual risk of progression to cirrhosis and the annual risk of death at each stage of the disease.
Authors: Jingbiao Chen; Rosa Martin-Mateos; Jiahui Li; Ziying Yin; Jie Chen; Xin Lu; Kevin J Glaser; Taofic Mounajjed; Hiroaki Yashiro; Jenifer Siegelman; Christopher T Winkelmann; Jin Wang; Richard L Ehman; Vijay H Shah; Meng Yin Journal: Alcohol Clin Exp Res Date: 2021-09-05 Impact factor: 3.928
Authors: Ashwin D Dhanda; Hannah Allende; Victoria Allgar; Jackie Andrade; Matthew Peter Bailey; Lynne Callaghan; Laura Cocking; Elizabeth Goodwin; Annie Hawton; Christopher Hayward; Ben Hudson; Alison Jeffery; Angela King; Victoria Lavers; Joe Lomax; C Anne McCune; Richard Parker; Christopher Rollinson; Jonny Wilks; E Siobhan Creanor Journal: BMJ Open Date: 2022-05-18 Impact factor: 3.006
Authors: Anton L V Avanceña; Nicholas Miller; Sarah E Uttal; David W Hutton; Jessica L Mellinger Journal: J Hepatol Date: 2020-12-14 Impact factor: 30.083